|
MechanismAPOC3 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date03 May 2019 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date06 Jul 2018 |
100 Clinical Results associated with Akcea Therapeutics Ireland Ltd.
0 Patents (Medical) associated with Akcea Therapeutics Ireland Ltd.
100 Deals associated with Akcea Therapeutics Ireland Ltd.
100 Translational Medicine associated with Akcea Therapeutics Ireland Ltd.